Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

With MANKIND's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 43.158974
debtToEquity 4.468000
earningsGrowth -0.165000
revenueGrowth 0.239000
grossMargins 0.701830
operatingMargins 0.197370
trailingEps 50.700000
forwardEps 61.700000

MANKIND's low earnings and revenue growth suggest shrinking profits are likely. This could reflect broader financial struggles, signaling that the company might face difficulties in sustaining its profitability.
Mankind Pharma Limited's negative gross and operating margins point to financial difficulties, as the company is unable to generate profit from its core operations or production. This could signal broader problems in cost management or declining sales.
MANKIND's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for MANKIND's financial growth.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

MANKIND's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


A recent buy bias from analysts toward MANKIND may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that MANKIND might be an appealing option for those looking to grow their wealth through stock market investments.